Clusterin expression was challenged using the drug OGX-011, an antisense oligonucleotide that showed a potentiating effect on various FDA-approved anticancer chemotherapeutics during clinical trials [90]; however, no trial in pancreatic cancer has been programmed yet [91]. The gene discussed is CLU; the disease is pancreatic neoplasm.